Lv31
350 积分 2025-04-23 加入
Advances and challenges in immunosuppressive antibody drug conjugates
14天前
已完结
Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer
1个月前
已完结
NuMA after 30 years: the matrix revisited
2个月前
已完结
Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates
2个月前
已完结
Natural product evodiamine-inspired medicinal chemistry: Anticancer activity, structural optimization and structure-activity relationship
2个月前
已完结
Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization
2个月前
已完结
An Intrinsically Hydrophilic Linker Enables a Stable, High-DAR Exatecan-Based HER2 ADC with Potent Antitumor Activity
2个月前
已完结
NH2-trimethyl lock (NH2-TML): a stable and effective adapter for exatecan-based antibody–drug conjugates
2个月前
已完结
Trimethyl Lock-2Cl (TML-2Cl): A self-cyclizing adapter for molecular release in antibody-drug conjugates
2个月前
已完结
Topoisomerase II-targeting anticancer clinical candidates and drugs: A critical analysis, unravelling molecular medicinal insights and promising research roadmap
2个月前
已完结
皖公网安备34019202002308
